

[View All Sections](#)

– **BOXED WARNING** (WHAT IS THIS?)

**WARNING: INFUSION REACTIONS and CARDIOPULMONARY ARREST**

**Infusion Reactions:** ERBITUX can cause serious and fatal infusion reactions [see *Warnings and Precautions (5.1)*, *Adverse Reactions (6)*]. Immediately interrupt and permanently discontinue ERBITUX for serious infusion reactions [see *Dosage and Administration (2.5)*].

**Cardiopulmonary Arrest:** Cardiopulmonary arrest or sudden death occurred in patients with squamous cell carcinoma of the head and neck receiving ERBITUX with radiation therapy or a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUX administration [see *Warnings and Precautions (5.2, 5.6)*].

[Hide](#)

- + HIGHLIGHTS OF PRESCRIBING INFORMATION
- + FULL PRESCRIBING INFORMATION: CONTENTS\*
- + 1 INDICATIONS AND USAGE
- + 2 DOSAGE AND ADMINISTRATION
- + 3 DOSAGE FORMS AND STRENGTHS
- + 4 CONTRAINDICATIONS
- + 5 WARNINGS AND PRECAUTIONS
- + 6 ADVERSE REACTIONS
- + 8 USE IN SPECIFIC POPULATIONS
- + 11 DESCRIPTION
- + 12 CLINICAL PHARMACOLOGY
- + 13 NONCLINICAL TOXICOLOGY
- + 14 CLINICAL STUDIES
- + 16 HOW SUPPLIED/STORAGE AND HANDLING
- + 17 PATIENT COUNSELING INFORMATION

[View All Sections](#)

